Pharmexa is presenting data from the first US clinical trial with the HER-2 Protein AutoVac™ vaccine at the 4th European Breast Cancer Conference (EBCC) in Hamburg Germany. The vaccine is well tolerated and safe and that it induces significant HER-2 specific antibodies in breast cancer patients. Based on these results Pharmexa plans the continued development of the vaccine through additional clinical investigations later this year.
The vaccine is designed to induce antibody responses against the HER-2 protein that is over expressed in many human cancers including some cancers of the breast. Breast cancer patients in the trial received 4 injections of the vaccine formulated in a standard aluminium adjuvant. HER-2 specific antibody responses were detected in 6 out of 10 patients in the trial. The first responses were detected after only 2 injections and were significantly boosted following subsequent immunizations. Additional responders were also detected after the 3rd and 4th immunizations. The vaccine was well tolerated and there were no serious safety concerns associated with the treatment.
Dr. Adam Brufsky principal investigator at Magee Women's Hospital in the US commented that "These are very promising Phase I results with a good safety profile as well as significant immune responses. This could lead to the development of an effective vaccine for HER-2 positive breast cancer patients. I am looking forward to the results from Pharmexa's planned Phase II study starting later this year that is designed to evaluate the clinical efficacy of the vaccine."
Cancer LifeCenter Article 9331